Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPα
PU.1 and C/EBPα are transcription factors essential for normal myeloid development. Loss-of-function mutation of PU.1 leads to an absolute block in monocyte/macrophage development and abnormal granulocytic development while that of C/EBPα causes a selective block in neutrophilic differentiation. In...
Gespeichert in:
Veröffentlicht in: | Nucleic acids research 1998-06, Vol.26 (12), p.3034-3043 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | PU.1 and C/EBPα are transcription factors essential for normal myeloid development. Loss-of-function mutation of PU.1 leads to an absolute block in monocyte/macrophage development and abnormal granulocytic development while that of C/EBPα causes a selective block in neutrophilic differentiation. In order to understand these phenotypes, we studied the role of PU.1 and C/EBPα in the regulation of myeloid target genes in vivo. Northern blot analysis revealed that mRNAs encoding receptors for M-CSF, G-CSF and GM-CSF, were expressed at low levels in PU.1⁻/⁻ fetal liver compared with wild type. To identify additional myeloid genes regulated by PU.1 and C/EBPα, we performed representational difference analysis (RDA), a PCR-based subtractive hybridization using fetal livers from wild type and PU.1 or C/EBPα knockout mice. By introducing a new modification of RDA, that of tissue-specific gene suppression, we could selectively identify a set of differentially expressed genes specific to myeloid cells. Differentially expressed genes included both primary and secondary granule protein genes. In addition, eight novel genes were identified that were upregulated in expression during myeloid differentiation. These methods provide a general strategy for elucidating the genes affected in murine knockout models. |
---|---|
ISSN: | 0305-1048 1362-4962 |
DOI: | 10.1093/nar/26.12.3034 |